Compare Gilead Sciences, Inc. (GILD) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares MSCI India ETF — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while iShares MSCI India ETF trades at $45.93 (market cap $5.73B). The key difference: Gilead Sciences, Inc. is far larger — about 31.8× iShares MSCI India ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares MSCI India ETF for 57 Days on average.
| GILD | INDA | |
|---|---|---|
Market Cap | $182.40B | $5.73B |
Volume | 4,469,821 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $55.29 |
52-Week Low | $116.74 | $45.42 |
Typical Hold Time | 111 Days | 57 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
INDA is trading at $46.12, down 1.31% with bearish technical signals dominating. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and U.S. tariff tensions. Technical indicators show oversold conditions with RSI readings below 30, while moving averages signal strong bearish momentum. Recent news highlights structural issues in India's banking-heavy market composition despite overall economic growth.
The outlook remains cautious given India's energy security challenges and external trade pressures. Investment opportunity exists for long-term investors betting on India's growth story at current discounted levels, but risks include persistent power shortages, agricultural output concerns, and global trade tensions that could further pressure the ETF's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
